Artificial Intelligence impact on decision-making regarding short-term ADT with prostate radiotherapy: ASTuTE clinical trial interim results.

This interim analysis of a multicentre implementation trial (n = 200) evaluated a multimodal artificial intelligence biomarker's impact on shared short-term androgen deprivation therapy (ST-ADT) decisions in intermediate-risk prostate cancer (IR-PC). Biomarker testing altered 27.5% (CI: 21.4-34.2%) of final decisions. ST-ADT use significantly decreased: 70.3% (CI: 58.5-80.3%) of patients initially electing ST-ADT changed to 'NO', versus a 2.4% (CI: 0.5-6.8%) shift to 'YES' (p < 0.001). Decision changes were significantly greater in unfavourable versus favourable IR-PC (35% v 4%; p < 0.001). These interim findings demonstrate a significant shift toward de-escalation.